# A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants

> **NCT06214481** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 20 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Rocatinlimab

## Key facts

- **NCT ID:** NCT06214481
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-23
- **Primary completion:** 2024-05-27
- **Final completion:** 2024-06-05
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06214481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06214481, "A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06214481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*